Norton Scientific Fraud Commentaries

Norton Scientific by Brad Kepler Norton Scientific Research Scam Fraud Detection
Cancer society decries drug shortage 29March 2012 (NortonScientificCollection) - It is unacceptable that some cancer patients can't readily get the drugs they need because of supply problems, the Canadian Cancer Society says. The society is hearing from worried patients and doctors across the country, said Dan Demers, the group's director of public issues.
"We shouldn't have to wait for a crisis to respond," said Demers. The cancer society urged the federal government to: Ensure there is mandatory listing of unavailable drugs by drug manufacturer. Develop early warning systems to identify potential drug shortages. Put systems in place to prevent shortages from escalating. Work with other jurisdictions to investigate the root causes of the shortages and act to prevent them where possible.
Canada's supply of injectable drugs such as painkillers, antibiotics and anesthetics became more precarious following a fire in the boiler room at Sandoz Canada's plant in Boucherville, Que. "Production has resumed in the portion of the plant that was not directly affected by the incident, which took place on March 4," the company said in a email to CBC News on Monday. "Our objective is to restore previous levels of supply as soon as possible, and we will make every effort to meet medical needs, while ensuring consistent high quality standards."
Rationing supplies The company was unable to...

Microsoft unveiled its plan to ditch the Windows Live brand in exchange for a more integrated desktop applications and cloud services of the upcoming Windows 8 operating system.
Windows Live was introduced in 2005 and though its services like Hotmail and SkyDrive are being used by over 500 million users, Microsoft noted that they “did not meet their expectations of a wholly connected experience”. Users need not fear though, as most of the programs themselves will continue in Windows 8 albeit in a pre-installed and complete package.
“Windows Live services and apps were built on versions of Windows that were simply not designed to be connected to a cloud service for anything other than updates, and as a result, they felt ‘bolted on’ to the experience.” Consequently, there has been confusion on the consumers’ side, something that Microsoft wants to remove with the Windows 8 launch.
With Windows 8, a user only needs one Microsoft account, referred to as an “identity service”. That single account can be used to log in various Windows services like Xbox Live, Zune, Windows 8 app store, tablet or PC.
“Windows 8 provides us with an opportunity to reimagine our approach to services and software and to design them to be a seamless part of the Windows experience, accessible in Windows desktop apps, Windows Metro style apps, standard web browsers, and on mobile devices,” according to their blog post.
This integration allows for syncing ...

Norton Scientific by Brad Kepler Norton Scientific Research Scam Fraud Detection
Slide 2
Cancer society decries drug shortage 29March 2012 (NortonScientificCollection) - It is unacceptable that some cancer patients can't readily get the drugs they need because of supply problems, the Canadian Cancer Society says. The society is hearing from worried patients and doctors across the country, said Dan Demers, the group's director of public issues.
Slide 3
"We shouldn't have to wait for a crisis to respond," said Demers. The cancer society urged the federal government to: Ensure there is mandatory listing of unavailable drugs by drug manufacturer. Develop early warning systems to identify potential drug shortages. Put systems in place to prevent shortages from escalating. Work with other jurisdictions to investigate the root causes of the shortages and act to prevent them where possible.
Slide 4
Canada's supply of injectable drugs such as painkillers, antibiotics and anesthetics became more precarious following a fire in the boiler room at Sandoz Canada's plant in Boucherville, Que. "Production has resumed in the portion of the plant that was not directly affected by the incident, which took place on March 4," the company said in a email to CBC News on Monday. "Our objective is to restore previous levels of supply as soon as possible, and we will make every effort to meet medical needs, while ensuring consistent high quality standards."
Sl...

Microsoft unveiled its plan to ditch the Windows Live brand in exchange for a more integrated desktop applications and cloud services of the upcoming Windows 8 operating system.
Windows Live was introduced in 2005 and though its services like Hotmail and SkyDrive are being used by over 500 million users, Microsoft noted that they “did not meet their expectations of a wholly connected experience”. Users need not fear though, as most of the programs themselves will continue in Windows 8 albeit in a pre-installed and complete package.
“Windows Live services and apps were built on versions of Windows that were simply not designed to be connected to a cloud service for anything other than updates, and as a result, they felt ‘bolted on’ to the experience.” Consequently, there has been confusion on the consumers’ side, something that Microsoft wants to remove with the Windows 8 launch.
With Windows 8, a user only needs one Microsoft account, referred to as an “identity service”. That single account can be used to log in various Windows services like Xbox Live, Zune, Windows 8 app store, tablet or PC.
“Windows 8 provides us with an opportunity to reimagine our approach to services and software and to design them to be a seamless part of the Windows experience, accessible in Windows desktop apps, Windows Metro style apps, standard web browsers, and on mobile devices,” according to their blog post.
This integration allows for syncing ...

Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.
The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.
Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.
Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.
According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.
The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there...

As one of the leading providers of classic literature commentaries/reviews online, Norton Collection of Classic and Scientific Literature keeps a wide array of titles from prominent to obscure authors of different genres and era.

To ensure the you will get utmost quality service from Norton Collection of Classic and Scientific Literature, we constantly update our collection to include newer titles and accomodate requested reviews of users whenever we can.

And with so many titles on our archives, it is essential for readers to be able to search something they want quickly. You’ll be delighted to know that you can zero in on your target books by giving us the author name, relevant keywords or the title itself — and wait for the results just in seconds!

For those who just want to browse around and find other interesting books on their favorite category, Norton Collection of Classic and Scientific Literature has a Bookshelf section. Every title we have comes with complete description and recommendations.

SEE MORE DETAILS : norton-scientificcollection.com

NORTON COLLECTION OF CLASSIC AND SCIENTIFIC LITERATURE
One of the leading providers of classic literature commentaries/reviews online.
Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.

Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.

“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.

The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.

Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.

Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.

According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.

The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the caus...

Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.
The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.
Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.
Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.
According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.
The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there...

As one of the leading providers of classic literature commentaries/reviews online, Norton Collection of Classic and Scientific Literature keeps a wide array of titles from prominent to obscure authors of different genres and era.

To ensure the you will get utmost quality service from Norton Collection of Classic and Scientific Literature, we constantly update our collection to include newer titles and accomodate requested reviews of users whenever we can.

And with so many titles on our archives, it is essential for readers to be able to search something they want quickly. You’ll be delighted to know that you can zero in on your target books by giving us the author name, relevant keywords or the title itself — and wait for the results just in seconds!

For those who just want to browse around and find other interesting books on their favorite category, Norton Collection of Classic and Scientific Literature has a Bookshelf section. Every title we have comes with complete description and recommendations.

SEE MORE DETAILS : norton-scientificcollection.com